Relevant bibliographies by topics / Hormone replacement therapy (HRT)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Hormone replacement therapy (HRT)'

Author: Grafiati
Published: 4 June 2021
Last updated: 27 April 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Hormone replacement therapy (HRT).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Hormone replacement therapy (HRT)"

1

Hillard, Amanda. "Hormone replacement therapy (HRT)." Nursing Standard 8, no. 18 (January 26, 1994): 31–36. http://dx.doi.org/10.7748/ns.8.18.31.s42.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Quilliam, Susan. "Hormone replacement therapy (HRT)." Journal of Family Planning and Reproductive Health Care 30, no. 1 (January 1, 2004): 59–61. http://dx.doi.org/10.1783/147118904322702036.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Tsikoudas, A., X. Kochillas, and G. Vernham. "Reinke's oedema, hormones and hormone replacement therapy." Journal of Laryngology & Otology 120, no. 10 (May 23, 2006): 849–52. http://dx.doi.org/10.1017/s0022215106001630.

Full text
Abstract:
Objective: To study the implications of hormone replacement therapy (HRT) treatment in the pathogenesis of Reinke's oedema (via a possible pseudo-hypothyroidism effect), and also to study why the disease affects a predominantly post-menopausal female population.Design: Prospective case series study.Setting: Two teaching hospitals and two district general hospitals in Scotland, UK.Subjects: Thirty-three patients diagnosed with Reinke's oedema who presented in the out-patient department before or after treatment.Results: Thyroid function tests were normal in all but two cases. Only three patients were receiving HRT treatment.Conclusions: The study produced no evidence to support a relationship between HRT treatment and the pathogenesis of Reinke's oedema; this supports previous studies which concluded that thyroid function was not related to the development of Reinke's oedema. Some new ideas regarding hormonal factors in Reinke's oedema are discussed.
APA, Harvard, Vancouver, ISO, and other styles
4

McKinney, Karen A., and Trevor A. S. Buchanan. "Hormone replacement therapy and the eye." British Menopause Society Journal 6, no. 1 (March 1, 2000): 15–17. http://dx.doi.org/10.1258/136218000772085271.

Full text
Abstract:
Over the past 20 years there has been a revolution in the management of the menopause and the use of hormone replacement therapy (HRT). As the focus on postmenopausal health changes from symptomatic relief to the protective benefits of long-term HRT both ophthalmologists and gynaecologists can expect questions to be asked by their female patients about the influence of HRT on ophthalmic disease. This paper is a review of the current best evidence of effects of HRT on the eye. As oestrogens exert significant influences on the structure and function of ocular structures, we can assume that a reduction in oestrogen levels will have a negative effect on ocular physiology and may play a role in pathological processes in the eye. There is no evidence that HRT is harmful to ocular tissues; case reports point to a beneficial effect of HRT in relation to dry-eye, cataract and macular degeneration in post menopausal women. HRT probably suppresses the formation of cataracts in postmenopausal women and may reduce the incidence of serious retinal disease.
APA, Harvard, Vancouver, ISO, and other styles
5

Urmancheeva, A. F., and M. M. Burnina. "Hormone replacement therapy and malignant tumors." Journal of obstetrics and women's diseases 49, no. 1 (February 15, 2000): 58–62. http://dx.doi.org/10.17816/jowd88970.

Full text
Abstract:
The review on malignant tumors morbidity and its risk during hormone replacement therapy (HRT) is shown. The questions on possibilities of HRT in oncologic patients and the results of successful HRT management in rehabilitation of cervical cancer patients after surgical and and combined treatment are discussed.
APA, Harvard, Vancouver, ISO, and other styles
6

Daayana, S., and C. M. Holland. "Hormone replacement therapy and the endometrium." Menopause International 15, no. 3 (August 31, 2009): 134–38. http://dx.doi.org/10.1258/mi.2009.009027.

Full text
Abstract:
The life-expectancy for women has increased significantly in the 20th century, although the time of onset of menopause has not. Almost a third of a woman's life is now postmenopausal and therefore many postmenopausal women consider using hormone replacement therapy (HRT) to improve their quality of life. Most cases of endometrial carcinoma arise in postmenopausal women and this raises concern among patients and clinicians with regard to the safety of HRT in this age group. Whenever the use of HRT is considered, a careful consideration of the actual benefit in terms of symptom relief and quality of life must be balanced against the risks for each individual woman. This review discusses the effects of HRT on the endometrium and the evidence regarding HRT use and risk of endometrial cancer.
APA, Harvard, Vancouver, ISO, and other styles
7

&NA;. "Hormone Replacement Therapy (HRT) and Anaesthesia." Survey of Anesthesiology 46, no. 1 (February 2002): 56. http://dx.doi.org/10.1097/00132586-200202000-00055.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Brighouse, D. "Hormone replacement therapy (HRT) and anaesthesia." British Journal of Anaesthesia 86, no. 5 (May 2001): 709–16. http://dx.doi.org/10.1093/bja/86.5.709.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Holloway, Debby. "Guide to Hormone replacement therapy (HRT)." Practice Nursing 33, Sup3a (March 1, 2022): S1—S5. http://dx.doi.org/10.12968/pnur.2022.33.sup3a.s1.

Full text
Abstract:
The menopause can affect all women, and the way it impacts them will be individual and unique. Some women will have minimal symptoms and will not require any medical treatment; others may require lifestyle changes and support. However, some will have significant symptoms that would impact on their quality of life, daily functioning and work. These women will require help in the form of lifestyle adjustment, prescribed alternatives, complementary therapies or hormone replacement therapy (HRT) – or a combination of all of the above. This Guide will provide an overview of HRT, the symptoms women experience and how these can be managed with HRT.
APA, Harvard, Vancouver, ISO, and other styles
10

Sestak, Ivana, Roseann Kealy, Robert Edwards, John Forbes, and Jack Cuzick. "Influence of Hormone Replacement Therapy on Tamoxifen-Induced Vasomotor Symptoms." Journal of Clinical Oncology 24, no. 24 (August 20, 2006): 3991–96. http://dx.doi.org/10.1200/jco.2005.04.3745.

Full text
Abstract:
Purpose Tamoxifen is an effective drug, but its role in prevention is limited by its adverse effect profile. Non–life-threatening adverse effects, such as vasomotor symptoms, have an important influence in its use for prevention. Vasomotor symptoms were evaluated according to follow-up time, severity, and use of hormone replacement therapy (HRT) in a retrospective analysis. Patients and Methods In the International Breast Cancer Intervention Study-I study, 7,154 women at increased risk of breast cancer were randomly assigned to either tamoxifen 20 mg/d or placebo for 5 years. Women gave detailed information on any vasomotor symptoms at each 6-month follow-up visit. Results Hot flushes were reported more often in the tamoxifen group than in the placebo group (70.6% v 57.1%, respectively; odds ratio, 1.80; 95% CI, 1.63 to 1.99). Severe hot flushes were more strongly related to tamoxifen. In the tamoxifen arm, more women taking HRT at entry experienced hot flushes in the first 6 months than those who did not take HRT (60.8% v 49.2%, respectively; P = .09). In contrast, women on placebo taking HRT at entry experienced fewer hot flushes than women who stopped HRT (22.9% v 34.3%, respectively; P = .03). Furthermore, for women who first began HRT in the first 6 months of the trial compared with women who did not begin HRT, HRT seemed to be much more effective in controlling hot flushes in months 6 to 12 in the placebo arm (47.9% v 20.4%, respectively) than in the tamoxifen arm (51.4% v 39.0%, respectively). Conclusion HRT use at entry or during the trial was not effective in alleviating hot flushes for women in the tamoxifen arm. Our retrospective study suggests that estrogen-based HRT has limited effectiveness among women receiving tamoxifen.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Hormone replacement therapy (HRT)"

1

Björn, Inger. "Hormone replacement therapy and effects on mood." Doctoral thesis, Umeå universitet, Obstetrik och gynekologi, 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-94115.

Full text
Abstract:
Background: During the past 5 decades, hormone replacement therapy (HRT) has been used, and appreciated for its beneficial effects, by millions of women in their menopause. As treatment for climacteric symptoms, estrogen is outstanding, and effects on hot flushes, vaginal dryness, and insomnia have been widely documented. The increased risks of venous thrombosis and breast cancer, however, restrict the use of estrogen. Estrogen treatment in women with a remaining uterus includes a progestin, added to protect the endometrium from hyperplasia and malignancies. The long-standing clinical impression, that progestin addition negatively influences mood, has been discussed in previous studies. Mood deterioration is, however, not mortal, although mood is important to the wellbeing and daily functioning of women treated with hormones. Studies of the mental side effects of HRT add to our understanding of steroid effects in the brain. Aims and methods: In our studies, we aimed to establish to what extent negative side effects cause women to discontinue HRT, and find out which drug compounds lead to mood deterioration. The questions asked were whether the type and dose of progestin and the estrogen dose during the progestin addition influence the mood and physical symptoms during sequential HRT. Compliance with HRT and reasons for discontinuing the therapy were evaluated in a retrospective longitudinal follow-up study. Treatment effects were studied in three randomized, double-blind, cross-over trials. During continuous estrogen treatment, effects of sequential addition of a progestin were studied by comparing two different progestins, medroxyprogesterone acetate (MPA) andnorethisterone acetate (NETA), comparing different doses of the same progestin, MPA, and comparing two doses of estrogen during addition of the same dose of MPA. The main outcome measure was the daily rating on mood and physical symptoms kept by the participants throughout the studies. The clinical trials were carried out at three gynecological centers in northern Sweden. Results and conclusions: Besides fear of cancer and a wish to determine whether climacteric symptoms had meanwhile disappeared, negative side effects was the most common reason or discontinuing HRT. Tension in the breasts, weight gain, a depressed mood, abdominal bloating, and irritability were the most important side effects seen both in women who continued HRT and in women who had discontinued the therapy. In our clinical trials, we showed that addition of a progestin to estrogen treatment induces cyclic mood swings characterized by tension, irritability, and depression, as well as increased breast tension, bloatedness, and hot flushes. Women with a history of premenstrual syndrome (PMS) appeared to be more sensitive to the progestin addition and responded with lower mood scores compared with women without previous PMS. In our studies, MPA provoked depressed mood to a lesser extent than did NETA. Surprisingly, the higher dose of MPA (20 mg) enhanced the mood, compared with 10 mg, when added to estrogen treatment. In women continuously treated with 3 mg estradiol, mood and physical symptoms worsened during the progestin addition, as compared with treatment with 2 mg estradiol. The negative side effects seen during sequential HRT have much in common with symptoms seen in the premenstrual dysphoric disorder (PMDD), which is a psychoneuroendocrine disorder with psychiatric expression. Explanations for treatment effects on mood are likely to be found in drug interactions with neurotransmitter systems of the brain.

Diss. (sammanfattning) Umeå : Umeå universitet, 2003


digitalisering@umu
APA, Harvard, Vancouver, ISO, and other styles
2

Hillard, Timothy Charles. "The prevention of postmenopausal osteoporosis : effects of oral and transdermal hormone replacement therapy." Thesis, University of Southampton, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.295875.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ödmark, Inga-Stina. "Hormone replacement therapy : benefits and adverse effects." Doctoral thesis, Umeå universitet, Obstetrik och gynekologi, 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-243.

Full text
Abstract:
Background: Numerous studies have shown that estrogen replacement therapy (ERT) is an effective treatment for vasomotor symptoms, insomnia and vaginal dryness. Beneficial effects have also been shown on lipid patterns and on the incidence of osteoporotic fractures. As ERT increases the risk of endometrial adenocarcinoma, combinations with various progestogens have been developed in order to protect the endometrium. However, the addition of progestogens tends to reduce the beneficial effects of estrogens on mood, cognition and lipid metabolism. The added progestogen often causes side effects such as irritability and depression. There is evidence that the effect on wellbeing varies between women and with the type of progestogen used. Women who prefer to avoid withdrawal bleedings can be given continuous combined hormone replacement therapy (HRT). Unfortunately, irregular bleedings are common at the beginning of treatment and reduces compliance. Recently, several studies have reported an increased risk of breast cancer and venous thrombosis, and therefore long-term treatment with HRT for women without climacteric symptoms is no longer recommended. The ongoing debate has, for the time being, resulted in a recommendation that improving quality of life (QoL) by treatment of climacteric symptoms should be the only indication for prescribing HRT. Aims and methods: The aims of the study were to investigate bleeding patterns, changes in wellbeing at onset and during long-term treatment, and lipid and lipoprotein profiles with two different types of continuous combined HRT. In addition, women starting, and women switching from mainly sequential HRT were compared. The design was a randomised, double-blind, one year, prospective, multicentre study including 249 healthy postmenopausal women who were given continuous daily oral treatment with either combined 0.625mg conjugated estrogen (CE) and 5mg medroxyprogesterone acetate (MPA) or combined 2mg 17β - estradiol (E2) and 1mg norethisterone acetate (NETA). Bleedings, if any, were recorded daily throughout the study. The main outcome measures (changes in wellbeing and climacteric symptoms) consisted of daily ratings of 12 items on a validated symptom scale. Serum concentrations of lipids and lipoproteins were measured at baseline and after one year of treatment. Results and conclusions: The majority of drop-outs were confined to the first three months, and the main reasons were bleedings and/or decreased wellbeing. Drop-outs were three times more common in the E2/NETA group. During the first month, 67% of the women reported irregular bleedings. The number of bleeding days decreased on both treatments during the first four months. Treatment with CE/MPA resulted in less irregular bleedings and a shorter time to amenorrhoea compared to E2/NETA. As expected, "starters" experienced more sweats than "switchers" at the onset of treatment, but both groups improved significantly. Side effects such as breast tenderness, swelling, depression and irritability appeared during the first treatment week in both groups. The side effects of HRT appeared much more quickly than the benefits and were more frequent in women with a history of premenstrual syndrome (PMS). Breast tenderness was more common in the E2/NETA group throughout the whole study period. Apart from that, there were no differences between the two treatment regimens as regards effects on well-being at the end of the study. Lipoprotein(a) levels, an important risk factor for cardiovascular disease, decreased in both treatment groups. Triglyceride levels increased in women treated with CE/MPA, and levels of total cholesterol, high density lipoprotein and low density lipoprotein fell in the E2/NETA group. In conclusion, treatment with E2/NETA caused more bleeding problems than treatment with CE/MPA. CE/MPA was better tolerated than E2/NETA at the beginning of the study, but among the women remaining in the study there was no difference in QoL between the two treatment groups. HRT counselling should take into account that a history of PMS increases the likelihood of side effects and that these may precede any beneficial effects. Both treatments produced beneficial effects on lipid and lipoprotein levels, and neither of the regimens was superior in this respect.
APA, Harvard, Vancouver, ISO, and other styles
4

Talbi, Oussama. "Synthesis of Homo A-CD Estrogens for Potential Use in Hormone Replacement Therapy." Thesis, Université d'Ottawa / University of Ottawa, 2015. http://hdl.handle.net/10393/32082.

Full text
Abstract:
Hormone replacement therapy (HRT) has been subject to much debate due to concerns that long term use of such treatment of menopause increases the risk of breast and uterine cancer. This is thought to be caused by estradiol (1) binding to the estrogen receptor α (ERα) resulting in increased cell proliferation. Another possible mechanism relates to toxicity of the estrodiol metabolites, which are thought to be genotoxic ortho-quinones. In a previous project, a series of A-CD estrogens (2) were synthesised as non-carcinogenic estradiol agonists where the cis CD ring junction was thought to be the cause of the desirable selectivity for ERβ. In this thesis, homo A-CDs were synthesised (3) with expansion of the D ring thought to increase the selecitivty for ERβ. Relative Binding Affinities (RBA) were determined with selectivity to ERα and ERβ. Most ligands showed decreased selectivity when compared to the original A-CD series. However, compounds carrying the CF3 moiety continued to show very high potency. In addition, novel synthetic routes were employed in the preparation of certain compounds.
APA, Harvard, Vancouver, ISO, and other styles
5

Duncan, Ann Carolyn. "Hormone replacement therapy and vascular protection : the influence of oestrogen on the endothelium." Thesis, University of Glasgow, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.482821.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Williamson, Tanika. "Hormone Replacement Therapy (HRT) Modulates Peripheral and Central Auditory System Processing With Aging." Scholar Commons, 2016. http://scholarcommons.usf.edu/etd/6604.

Full text
Abstract:
After the findings were reported for the Women’s Health Initiative (WHI) study in the past decade, there has been a significant decline in the overall use of hormone replacement therapy (HRT) among women. However, there are still millions of middle-aged, menopausal women in the U.S. who are currently undergoing hormone therapy. Their reasons for continuing treatment include relief of severe menopausal symptoms, aid in the management of osteoporosis and reduction in the risk of colon cancer (Ness et al., 2005). The purpose of the following investigation was to evaluate the impact of HRT on the central and peripheral auditory systems both during and after treatment. Over the course of the study, hormone treatments were administered to female aging CBA/CaJ mice to observe what effects estrogen (E) and progestin (P) have on the peripheral and central auditory systems. Female CBA/CaJ middle age mice were ovariectomized and placed into 4 HRT groups (E, P, E+P and Placebo [Pb]). Hormone treatment lasted 6 months followed by a recovery/washout period of 1 month. During this time, electrophysiology tests such as auditory brainstem responses (ABR) and ABR gap in noise (GIN) were used to measure neural activity for the auditory nerve and brainstem. Distortion product otoacoustic emission (DPOAE) testing was also implemented to assess the functional status of the outer hair cells (OHC) and their ability to amplify sound in the cochlea. After 6 months of treatment, animals treated with E exhibited the least amount of changes in ABR thresholds and ABR GIN amplitudes than any other subject groups. Interestingly, P animals exhibited an abrupt increase in ABR thresholds only 3 months after treatment; however, for ABR GIN amplitude levels a progressive reduction observed throughout the study. E+P and Pb animals showed signs of accelerated age-related hearing loss (ARHL) with significantly elevated ABR thresholds and dwindling ABR GIN amplitude levels. No significant signs of recovery were observed for any of the hormone groups. Therefore, in the present murine investigation, the effects of HRT were long lasting. To further expand on the results obtained for the electrophysiology tests, molecular biology experiments were performed to evaluate the expression of IGF-1R and FoxO3 in the cochlea during hormone therapy, from both in vitro and in vivo perspectives. Both genes play significant roles in the PI3K/AKT pathway and were specifically chosen because of their role in anti-apoptotic responses and cell survival. It was hypothesized that E attenuates the effects of ARHL via the PI3K/AKT pathway by up-regulating IGF-1R and FoxO3 to counteract the effects of oxidative stress in the aging mammalian cochlea. qPCR experiments were performed with stria vascularis (SV) lateral wall cells extracted from the cochlea of each animal in the hormone groups post-treatment (in vivo) and in SVK-1 cells treated with HRT over various lengths of time (in vitro) to evaluate the expression levels of IGF-1R and FoxO3. In-vivo experiments showed that the E-treated animals had significantly higher IG-1R levels compared to the other subject groups after treatment was discontinued. Similarly, IGF-1R levels steadily increased for E-treated SVK-1 cells over the course of hormone therapy, compared to P and E+P cells. FoxO3 expression, on the other hand, declined for all of the hormone-treated cells groups, relative to control SVK-1 cells (in vitro), and no statistical differences were detected for FoxO3 levels among the post-treatment animals (in vivo). These findings indicate that there is cross talk between E and IGF-1R involving the PI3K/AKT pathway, which contributes to the delayed onset of ARHL observed during HRT with E. Meanwhile, FoxO3 may not play a role in neuro-protective properties in the cochlea during HRT, as initially hypothesized.
APA, Harvard, Vancouver, ISO, and other styles
7

Banks, Emily. "Hormone replacement therapy : the epidemiology of use and effect on breast cancer screening in the UK." Thesis, London School of Hygiene and Tropical Medicine (University of London), 2000. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.312139.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ballard, Karen Dawn. "Women on the verge of HRT : factors influencing women's decisions about taking hormone replacement therapy." Thesis, Royal Holloway, University of London, 2001. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.396150.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Sinchugova, Nataliya. "Vilken betydelse har val av progestagen-typ respektive behandlingsregim för bröstcancerrisk vid hormonersättningsterapi (HRT)?" Thesis, Linnéuniversitetet, Institutionen för kemi och biomedicin (KOB), 2015. http://urn.kb.se/resolve?urn=urn:nbn:se:lnu:diva-43495.

Full text
Abstract:
Hormonersättningsterapi (HRT) används för att lindra vasomotoriska och urogenitala symtom associerade med klimakteriet. Eftersom behandling med enbart östrogen förknippats med endometriell hyperplasi och livmodercancer, tillsätts progestagener till östrogen-beredningar i HRT hos kvinnor med intakt livmoder för att motverka den proliferativa effekten av östrogen och förebygga cancerutveckling i livmodern. Sådan kombinerad HRT har emellertid associerats med ökad risk för bröstcancer. Vid kombinerad HRT används olika typer av progestagener och olika behandlingsregimer (kontinuerlig eller sekventiell tillförsel). Syftet med detta arbete var att undersöka vad som ökar risken för bröstcancer vid kombinerad HRT: valet av progestagen-typ eller vilken behandlingsregim (kontinuerlig/sekventiell) som används. Metoden som användes var en litteraturstudie som omfattade sju studier om HRT och bröstcancerrisk, vilka hämtades från databasen PubMed. Utifrån undersökta studier kan man dra slutsats att ökad risk för bröstcancer associeras med kombinerad östrogen-progestagen HRT jämfört med HRT med enbart östrogen och framför allt om man jämför kontinuerlig kombinerad HRT med sekventiell kombinerad HRT med ett dos-responsförhållande som bakomliggande grund. Progestagen-typ kan ha effekt på risken för bröstcancer men detta behöver undersökas ytterligare.
APA, Harvard, Vancouver, ISO, and other styles
10

Jackson, Barbara Ann, and n/a. "A study of baby boomer women and their expectations of menopause." University of Canberra. Professional & Community Education, 1996. http://erl.canberra.edu.au./public/adt-AUC20060801.142823.

Full text
Abstract:
This is a study of a generation of women who are about to enter the climacteric period of their life, the menopause. Born between the years 1946 and 1956 they have been the object of continuous scrutiny by various interest groups. Because they are seen to be unique, many acronyms and titles, the most noted being the 'Baby Boomers' have been attached to them. The women of this generation have been classed as a Very active' generation, leaving a clear mark on society and the re-emerging women's movement. As they near menopause they are approaching a stage that could be seen as their last reproductive transition. For many women there is no cultural ritual, nor a single story to guide them through this period They are however not without advice. The 'big voices' of the drug companies, the medical system and the media, all tender their guidance as the dominant voice. These women have been told what to do by experts throughout their whole lives. It seems 'expert advice' on their reproductive phases have been penned mostly by men in the interests of treating, controlling and saving them. Control of their body remains a key struggle, both physically and linguistically. The purpose of the research was to study the expectations of this post-war, Baby Boom generation of menopause. The study shows that some women have made decisions to embrace non-medical help and accept menopause as an inevitable transition, while others are willing to consider medical help to enhance their 'quality of life '. Believing it is time to look after themselves, it seems many women will take a pragmatic view and accept medical opinion that the menopause is a deficiency disease, even if this requires them to become part of the consumer driven/drug company push for a 'symptom free' menopause. They wish to remain untroubled and express a willingness to do whatever they need to fulfil this. Their fervent hope is that the menopause will not upset their career, family or 'life'. Consequently a large majority of these women will think about or actively pursue hormone replacement therapy.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Hormone replacement therapy (HRT)"

1

HRT: Hormone replacement therapy. New York: DK Pub., 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Royal College of Obstetricians and Gynaecologists. Problems with hormone replacement therapy (HRT). London: RCOG Press, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sexual chemistry: Understanding our hormones, the Pill and HRT. London: Cedar, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wren, Barry G. Menopause: Change, choice and HRT. Summer Hill, N.S.W: Rockpool Publishing, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

John, Kells, and Macgenn Christine, eds. The HRT solution. Garden City Park, N.Y: Avery Pub. Group, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Society, National Osteoporosis. What every woman needs to know about osteoporosis and hormone replacement therapy (HRT). Bath: The National Osteoporosis Society, 1990.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Robert, Schweizer, ed. HRT: Licensed to kill and maim : the unheard voices of women damaged by hormone replacement therapy. London: Slingshot, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Abernethy, Kathy. The menopause and HRT. 2nd ed. Edinburgh: Ballière Tindall, 2002.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

M, Beale C., ed. The cardioprotective role of HRT: A clinical update. New York: Parthenon Pub. Group, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Chaplin, Steve. Prescribing in hormone replacement therapy (HRT): A distance learning pack for community pharmacists on discussing therapeutics with GPs. [U.K.]: Centre for Pharmacy Postgraduate Education, Distance Learning, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Hormone replacement therapy (HRT)"

1

Bartl, Reiner, and Christoph Bartl. "Hormone Replacement Therapy (HRT)." In The Osteoporosis Manual, 167–73. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-00731-7_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bartl, Reiner, and Christoph Bartl. "Hormone Replacement Therapy (HRT)." In Bone Disorders, 177–83. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-29182-6_26.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Caretto, Marta, and Tommaso Simoncini. "Hormone Replacement Therapy (HRT)." In Endocrinology, 1–18. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-03594-5_18-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Caretto, Marta, and Tommaso Simoncini. "Hormone Replacement Therapy (HRT)." In Endocrinology, 349–66. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-14782-2_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nicholas, Nick. "Hormone Replacement Therapy (HRT)." In Medicolegal Issues in Obstetrics and Gynaecology, 317–23. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-78683-4_58.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schneider, H. P. G. "General Aspects of Worldwide HRT Use." In Hormone Replacement Therapy and Osteoporosis, 1–28. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-662-04021-8_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Aono, T., K. Azuma, and M. Irahara. "General Aspects of HRT in Japan." In Hormone Replacement Therapy and Osteoporosis, 29–41. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-662-04021-8_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Ohkura, T., K. Isse, K. Tanaka, K. Akazawa, M. Hamamoto, and N. Iwasaki. "HRT and Brain Function — Clinical Aspects." In Hormone Replacement Therapy and Osteoporosis, 75–97. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-662-04021-8_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Aso, T. "HRT and Climacteric Symptoms: Characteristics in Japanese Women." In Hormone Replacement Therapy and Osteoporosis, 165–70. Berlin, Heidelberg: Springer Berlin Heidelberg, 2000. http://dx.doi.org/10.1007/978-3-662-04021-8_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Houlberg, Magda. "Endocrinology, Hormone Replacement Therapy (HRT), and Aging." In Transgender and Gender Nonconforming Health and Aging, 21–35. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-319-95031-0_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Hormone replacement therapy (HRT)"

1

Vieira, Amanda Cristina de Souza, Antônio Pedro Oliveira de Vasconcelos, Jaqueline Maria Pinheiro de Araujo, Juliana Comin Müller, Larissa de Cassia Afonso Magalhães, Renato Duarte da Silva, Ricardo Baroni Vieira, and Fabiana Candida de Queiroz Santos Anjos. "EPIDEMIOLOGICAL RELATIONSHIP BETWEEN HORMONE REPLACEMENT THERAPY AND BREAST CANCER." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2090.

Full text
Abstract:
Objective: The aim of this study was to epidemiologically analyze the hormone replacement therapy (HRT) and the emergence of breast cancer. Methodology: This is an article review from the databases such as LILACS, SciELO, Bireme, and Medscape, utilizing the keywords: menopause, HRT, breast cancer and complications, employing the use of connectors when necessary. This review aims to elucidate what has been published in the last years about the usage of hormone therapy and the emergence of breast cancer since there are disagreements between the literature. Results: The analysis displayed positive effects during the usage of HRT, such as maintenance of bone density, prevention of fractures, and cardiovascular events in patients with no previous changes in this system, and also showed us a strong relationship between HRT and the incidence of breast cancer in menopausal women with a focus into the imposing time of use ratio. Meanwhile, this development risk of breast CA can be reduced in the long run with the withdrawal of the previously initiated therapy. The progesterone HRT has been shown to have lower risks in association with estrogen than when compared with the association of synthetic progestins and estrogen. Associations have similar results for oral and skin HRT. In patients using the postmenopausal hormone therapy, the risk of mortality from breast cancer was reduced in patients with exposure for a maximum of 5 years, more than 5–10 years, or more than 10 years. Conclusion: In view of the exposure, it is considered that the HRT is more beneficial than malefic to the life and health of women. Meanwhile, the risk of breast CA goes up while the HRT time stretches over the years. Thus, it is necessary to individually evaluate the benefits and risks to better identify the therapy that should be utilized.
APA, Harvard, Vancouver, ISO, and other styles
2

Yokota, Megumi, Wataru Yamagami, Shiyoko Kitazawa, Satoko Tanimoto, Takuma Yoshimura, Kensuke Sakai, Takayuki Chiyoda, Takashi Iwata, Koji Banno, and Daisuke Aoki. "Profiling of menopausal symptoms and therapeutic effects of hormone replacement therapy (HRT) in endometrial cancer survivors." In The 7th Biennial Meeting of Asian Society of Gynecologic Oncology. Korea: Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology, 2021. http://dx.doi.org/10.3802/jgo.2021.32.s1.e29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ragaz, Joseph, Shayan Shakeraneh, Hong Qian, Hubert Wong, John J. Spinelli, and Kenneth S. Wilson. "Abstract PS7-05: Estrogen-based hormone replacement therapy [E-HRT] reduces all-cause, breast cancer, and Alzheimer's dementia mortality." In Abstracts: 2020 San Antonio Breast Cancer Virtual Symposium; December 8-11, 2020; San Antonio, Texas. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.sabcs20-ps7-05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

McKian, KP, MH Frost, SD Maloney, RA Vierkant, DW Visscher, and LC Hartmann. "Abstract P6-09-03: No Increased Breast Cancer Risk with Hormone Replacement Therapy (HRT) in Women with Benign Breast Disease." In Abstracts: Thirty-Third Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 8‐12, 2010; San Antonio, TX. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/0008-5472.sabcs10-p6-09-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ragaz, J., H. Qian, H. Wong, KS Wilson, S. Shakeraneh, and JJ Spinelli. "Abstract P6-13-04: Estrogen-alone based hormone replacement therapy (HRT) reduces breast cancer (BrCa) incidence and mortality whereas estrogen plus progestin Provera based HRT increases both BrCa incidence and BrCa mortality: A comparative analysis of Women's Health Initiative trials." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-13-04.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ragaz, J., S. Shakeraneh, H. Qian, KS Wilson, H. Wong, and JJ Spinelli. "Abstract P6-13-06: Estrogen-based hormone replacement [HRT] therapy is substantially more effective than tamoxifen in reducing breast cancer mortality and breast cancer case fatality ratio: Emergence of a new paradigm." In Abstracts: 2018 San Antonio Breast Cancer Symposium; December 4-8, 2018; San Antonio, Texas. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-p6-13-06.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ragaz, J., N. Le, J. Budlovsky, and J. Spinelli. "Protective Effect of Estrogen (E2) and Increased Risk of E2 Plus Progestin (Prog) on Breast Cancer (BrCa). The 2009 Review of the Women's Health Initiative (WHI) Hormone Replacement Therapy (HRT) Published Trials." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-908.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Zhang, P., and J. G. Zein. "Menopausal Hormone Replacement Therapy and Risk of Asthma." In American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a7089.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Dembo, Anna, and Geoffrey Greene. "Abstract 5044: Reducing breast cancer risk with hormone replacement therapy." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Triebner, Kai, Simone Accordini, Lucia Calciano, Ane Johannessen, Bryndís Benediktsdóttir, Ersilia Bifulco, Pascal Demoly, et al. "Hormone replacement therapy may preserve lung function during reproductive aging." In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.oa4420.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Hormone replacement therapy (HRT)"

1

Huang, Xi. Hormone Replacement Therapy, Iron, and Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 2005. http://dx.doi.org/10.21236/ada448472.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Huang, Xi. Hormone Replacement Therapy, Iron, and Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, November 2004. http://dx.doi.org/10.21236/ada433028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Harvey, Jennifer A., Richard J. Santen, Gina R. Petroni, Viktor E. Bovberg, and Mark B. Williams. Increasing Mammographic Breast Density in Response to Hormone Replacement Therapy and Breast Cancer Risk. Fort Belvoir, VA: Defense Technical Information Center, October 2002. http://dx.doi.org/10.21236/ada412142.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Harvey, Jennifer A. Increasing Mammographic Breast Density in Response to Hormone Replacement Therapy and Breast Cancer Risk. Fort Belvoir, VA: Defense Technical Information Center, October 2003. http://dx.doi.org/10.21236/ada424557.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Modugno, Francesmary. Prospective Evaluation of Hormone Replacement Therapy, Body Mass Index, Estrogen Metabolism and Breast Cancer Risk. Fort Belvoir, VA: Defense Technical Information Center, July 2003. http://dx.doi.org/10.21236/ada417504.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Reding, Kerryn W. An Epidemiologic Study of Genetic Variation in Hormonal Pathways in Relation to the Effect of Hormone Replacement Therapy on Breast Cancer Risk. Fort Belvoir, VA: Defense Technical Information Center, October 2008. http://dx.doi.org/10.21236/ada501717.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Reding, Kerryn W. An Epidemiologic Study of Genetic Variation in Hormonal Pathways in Relation to the Effect of Hormone Replacement Therapy on Breast Cancer Risk. Fort Belvoir, VA: Defense Technical Information Center, April 2008. http://dx.doi.org/10.21236/ada486465.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Buist, Diana S., Katherine Newton, and Susan Reed. A Population-Based Randomized Trial to Assess the Effects of Short-Term Cessation of Hormone Replacement Therapy on Mammography Assessments and Breast Density. Fort Belvoir, VA: Defense Technical Information Center, June 2008. http://dx.doi.org/10.21236/ada488427.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mai, Zhefen, Chunli Lu, Zixun Zhuang, and Hongxia Ma. Effectiveness and safety of Er-xian Decoction (traditional Chinese medicine) for women with Primary ovarian insufficiency. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2021. http://dx.doi.org/10.37766/inplasy2021.11.0107.

Full text
Abstract:
Review question / Objective: To assess the effectiveness and safety of Er-xian Decoction in the treatment of primary ovarian insufficiency. Information sources: We will search the following electronic databases, including 3 English databases (PubMed, EMBASE, Cochrane Library) and 4 Chinese databases (China national knowledge infrastructure database, Wanfang database, Sinomed Database, and VIP database). The filters were English and Chinese language. The following key words in Title/Abstract or MeSH search headings are used: “Er-xian” and “Hormone replacement therapy” or “Femoston” or “Climen” and “Primary ovarian insufficiency” or “Ovarian failure” or “Premature ovarian failure” or “POI” and “random*” or “Randomized controlled trial”. In addition, we also search the grey literature such as conference proceedings and dissertations in CNKI and Wanfang database, and relevant trials will be searched in ClinicalTrial.gov database [20] and Chinese Clinical Trial Registry for unpublished trials and protocols. References of all included studies will be hand searched for additional eligible studies.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Hormone replacement therapy (HRT)' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography